IMPROVING THE PERCENTAGE OF PATIENTS ON CLOPIDOGREL WHO RECEIVED APPROPRIATE PRESCRIPTIONS IN PRIMARY CARE SETTINGS
DOI:
https://doi.org/10.63719/qbulletin.v1i34.312Keywords:
Clopidogrel, Primary care, Quality improvement studyAbstract
Clopidogrel, an antiplatelet agent, is often prescribed with aspirin for cardiovascular disease (CVD) patients. At the Klang District Health Office (DHO), concerns arose over its prolonged use. A verification study revealed that only 57% of clopidogrel prescriptions were appropriate. The indicator used was the percentage of patients on clopidogrel who received appropriate prescriptions, defined as adherence to recommended indications and duration (12 months). The study set a standard of 100% appropriate use and aimed to achieve this within three improvement cycles. A validated questionnaire was used to identify the contributing factors: lack of review and interventions by doctors (30%) and pharmacists (27%), incomplete clopidogrel indication and duration in prescriptions by doctors (24%), and high patient demands (19%). In Cycle 1 (July – December 2019), eight strategies were implemented, including the development of an in-house guideline, a clopidogrel assessment checklist, and continuous medical education (CME) sessions for doctors and pharmacists. A “Clopidogrel Intervention Mini Note” facilitated communication, while the Buku Rekod Ubat Pesakit (BRUP) provided essential patient details. A counselling checklist, standardised information delivery, and a clopidogrel counselling leaflet was created for patients. In Cycle 2 (January – June 2020), five strategies were implemented, including referring hospital and Klang DHO meeting to ensure discharge letters included both the diagnosis and clopidogrel duration. Additional measures included replacing the mini note with a prescription note, introducing QR codes for counselling pamphlets, and online counselling for patients. These interventions increased the appropriate clopidogrel prescribed from 57.0% to 87.2% in Cycle 1, to 94.2% in Cycle 2, and 98.0% in Cycle 3 (July 2022). Clopidogrel expenditure decreased substantially from MYR 42,705 to MYR 13,469 (Cycle 1), MYR 1,424 (Cycle 2), and MYR 438 (Cycle 3). To sustain improvements, we integrated the Clopidogrel Assessment Checklist into our work processes, promoting continuity of best practices among new doctors and pharmacists.
References
1. Dorsam RT, Murugappan S, Ding Z, Kunapuli SP. Clopidogrel: Interactions with the P2Y12 receptor and clinical relevance. Hematology. 2003;8(6):359–365. Available from: https://www.tandfonline.com/doi/abs/10.1080/10245330310001621260
2. Program Perkhidmatan Farmasi, Kementerian Kesihatan Malaysia. Formulari Ubat KKM (FUKKM) [Internet]. Available from: https://pharmacy.moh.gov.my/ms/apps/fukkm
3. Ean Pheng L, Syellawaty Ahmad N, Ping Wun C, Hairani Ishak I, Anthony T, Zhu Yun T. Improving the Appropriate Prescribing of Proton Pump Inhibitors (PPI) Among Referred Patients in Healthcare Clinics Under the Health Office of Klang District. Q Bulletin. 2022;1(31):72–79. Available from: https://myjms.mohe.gov.my/index.php/qbulletin/article/view/16884/110054
4. Norharlina S, Su Li W, Kar Mun N, Siti Fatimah AB, Sivasakthy V, Simran Kaur LS. Utilisation Review of Clopidogrel in Primary Care [Poster presentation]. Selangor Research Day; 2019 Sep.
5. Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet. 2004 Jul 24;364(9431):331–337.
6. NHS Greater Glasgow and Clyde. PostScript: Dual anti-platelet therapy. 2014;82:1–2. Available from: https://ggcmedicines.org.uk/media/uploads/postscript/1407_ps_82.pdf
7. Fornós-Garrigós A, Orozco-Beltrán D, Gil-Guillén VF, Puig-Barberà J, Fluixà C, Fernández A. Appropriateness of clopidogrel use according to current recommendations. Fam Pract. 2014;31(6):694–698. Available from: https://academic.oup.com/fampra/article/31/6/694/591414
8. Wijekoon CN. Audit of clopidogrel use in a medical clinic in a tertiary care hospital in Sri Lanka. J Ceylon Coll Physicians. 2016;47(2):82–85. doi:10.4038/jccp.v47i2.7788.
9. Ho WM, Hill C, Michael H, Winckel K. Evaluation of the duration of dual-antiplatelet therapy after percutaneous coronary intervention: a retrospective audit on the compliance with guidelines or cardiologist recommendation. J Pharm Pract Res. 2022;52(1):42–48. Available from: https://onlinelibrary.wiley.com/doi/10.1002/jppr.1780
10. George NE, Shukkoor AA, Joseph N, Palanimuthu R, Kaliappan T, Gopalan R. Implementation of clinical audit to improve adherence to guideline-recommended therapy in acute coronary syndrome. Egypt Heart J. 2022;74(1):4. Available from: https://pubmed.ncbi.nlm.nih.gov/35020077/
11. Jabri AM, Alqahtani A, Alhazmi A. Pharmacist role to enhance the prescribing of hospital discharge medications for patients after heart attack. Saudi Pharm J. 2020;28(4):463–469. doi:10.1016/j.jsps.2020.02.009.
12. National Health Systems Resource Centre (NHSRC). Prescription Audit Guidelines. New Delhi: Ministry of Health and Family Welfare, Government of India; 2021. Available from: https://nhsrcindia.org/sites/default/files/2021-07/1534_Prescription%20Audit%20Guidelines16042021.pdf
13. Jawatankuasa Farmasi Ambulatori, Bahagian Amalan dan Perkembangan Farmasi, Kementerian Kesihatan Malaysia. Garis Panduan Sistem Pendispensan Ubat Bersepadu (SPUB). Edisi ke-4. Putrajaya: Kementerian Kesihatan Malaysia; 2021.
14. Ministry of Health Malaysia, Academy of Medicine of Malaysia. Clinical Practice Guidelines: Primary & Secondary Prevention of Cardiovascular Disease 2017. Putrajaya: Ministry of Health Malaysia; 2017. Available from: https://www.moh.gov.my/moh/resources/Penerbitan/CPG/CARDIOVASCULAR/3.pdf


